Drug intelligence / Profile preview

measles, mumps, rubella, and varicella vaccine + diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and haemophilus influenzae type b vaccine

Development stage: Unknown
Lead developer: Merck
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous

Overview

ProQuad + Infanrix hexa refers to the concomitant administration of two separate vaccines: ProQuad (a live attenuated measles, mumps, rubella, and varicella vaccine) and Infanrix hexa (a hexavalent vaccine containing diphtheria and tetanus toxoids, acellular pertussis antigens, recombinant hepatitis B surface antigen, inactivated poliovirus, and Haemophilus influenzae type b conjugate). This combination is typically studied as a booster regimen in children aged 12 to 23 months to provide simultaneous protection against ten infectious diseases. Clinical data indicates that the co-administration is safe and immunogenic, with no significant interference between the various antigenic components.

Other names: MMRV + DTaP-HepB-IPV-Hib

Targets

CD46 (CD46 Molecule)BCR (Immunoglobulin G B Cell Receptor)PRR (Pattern recognition receptors)γδ TCR (T-cell receptor)SLAMF1 (SLAM family member 1)IDE (Insulin-degrading enzyme)

Beyond the preview

Go deeper on measles, mumps, rubella, and varicella vaccine + diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and haemophilus influenzae type b vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on measles, mumps, rubella, and varicella vaccine + diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and haemophilus influenzae type b vaccine.

Explore the full profile